August 25, 2025 4:32pm

A lot of the gains that we saw on Friday were the result of short covering; today’s selling pays for the early holiday escape, the brewskis, ‘tuners, vino and cook-outs; as any excuse, works for me!

News: AxoGen (AXGN -$1.47) the FDA has extended the Prescription Drug User Fee Act (PDUFA) goal date for its Biologics License Application (BLA) for Avance® Nerve Graft by 3 months to 12/5/25.

My insights are conveyed with a simplicity of language to highlight what is informative.

Never leave an investor uninformed!  

When you’re looking’ to escape to  some part of a vaca, take a look at the refrig for the mixers and the condiments, never forgeting the stuffed olives

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

 

Monday’s RegMed Investors’ (RMi) pre-open: Fits and starts … https://www.regmedinvestors.com/articles/14076

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Monday: The Dow closed DOWN -349.27 points or -0.77%, the S&P closed DOWN -27.59 points or -0.43% while the Nasdaq closed DOWN -47.243 points or -0.22%

  • Theme of the session, indexes were taking a hit after Friday's swings

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  • New home sales dropped -0.6% to a seasonally adjusted annualized rate of 652,000 units in July; well clear of the 628,000 expected by analysts. The prior month's reading was adjusted sharply upward. It now comes in at an annualized rate of 656,000, vs. the prior reported level of 627,000.

Monday’s advance/decline line opened negative with 8 incliners, 25 decliners and 2 flats ending with a negative close of 4 incliners, 29 decliners and 2 flats

Metrics:  Monday, the IBB was down -2.77%, the XBI was down -2.15% while the VIX was up +0.55 points or +3.87% at 14.77

 

Q3 – August – 8 negative and 8 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

Q2/25: June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes, May – 1 market holiday, 10 negative and 11 positive closes and April – 11 positive and 10 negative closes

 

Monday Closing UP (3 of 3) 

  • Intellia Therapeutics (NTLA +$0.86),
  • Adverum Biotechnologies (ADVM +$0.055),
  • Harvard Apparatus RT (OTCQB: HRGN +$0.05 after Friday’s $0.00)
  • Caribou BioSciences (CRBU +$0.03),

Flat (2)

  • Brainstorm Cell Therapeutics (BCLI
  • Compass Therapeutics (CMPX)

Monday’s Closing DOWN (10 of 29): 

  • Alnylam Pharmaceuticals (ALNY -$10.74 after Friday’s -$13.17),
  • BioNTech SE (BNTX -$5.81),
  • IQV Holdings (IQV -$3.21 after Friday’s +$5.74)
  • Sarepta Therapeutics (SRPT -$2.16),
  • Moderna (MRNA -$1.77 after Friday’s +$0.90),
  • AxoGen (AXGN -$1.47),
  • Vericel (VCEL -$1.24 after Friday’s +$1.59),
  • Ionis Pharmaceuticals (IONS -$0.87 after Friday’s -$0.55),
  • Ultragenyx Pharmaceuticals (RARE -$0.51),
  • Supernus Therapeutics (SUPN -$0.45 after Friday’s +$1.56)

 

The BOTTOM LINE:  Downside risks are rising …

The Dow, S&P and Nasdaq fell in downside Monday’s trade weighed by Fed Chair Powell's dovish pivot.

  • The benchmark S&P 500's sectors were mixed, with a downside bias within the market
  • The Nasdaq was off its highs, holding onto a 0.2% slide
  • Small caps also struggled, with the Russell 2000 index down -0.6%.
  • The 10-year Treasury yield rose 2 basis points to 4.28%.
  • Oil prices rose nearly 2%, sending West Texas intermediate futures up to nearly $65 a barrel.

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • Yet, I was again on target … this 4 a.m.

Earnings today: None

  • As earnings slowly come to the last few releases, collaborator revenues and runways has instilled share pricing with forward stability
  • Q2 results so far:  4 net incomes and 25 net losses of 29 releases to date

 

August: understand the “flow” …

  • 8/25 – Monday closed negative with 4 positive, 29 negative and 2 flats

Last week:

  • 8/22 – Friday closed positive with 30 positive, 4 negative and 1 flat
  • 8/21 - Thursday closed positive with 22 positive, 12 negative and 1 flat
  • 8/20 - Wednesday closed negative with 14 positive, 19 negative and 2 flats
  • 8/19 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
  • 8/18 - Monday closed positive with 18 positive, 17 negative and 0 flat

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Monday: Intellia Therapeutics (NTLA), Adverum Biotechnologies (ADVM) and Harvard Apparatus RT (OTCQB: HRGN)
  • Friday: IQVIA Holdings (IQV), Vericel (VCEL) and Supernus Therapeutics (SUPN)

The worst three (3) in the session: 

  • Monday: Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX) and IQVIA Holdings (IQV)
  • Friday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals IONS) and Agenus (AGEN)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.